BioSpace News Archive

In preparation for the launch of its next-generation Medicare Advantage Plans on January 1, 2019, Devoted Health has announced additional partnerships with premier hospitals in the Greater Orlando area.

Clean Recovery Centers (www.cleanrecoverycenters.com), an innovator in the treatment of addiction, has received Certification from LegitScript (www.legitscript.com), allowing them to be part of a discriminating group permitted to advertise on Google and Facebook.

Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce its first proprietary product, Comfort, which has been produced through wholly owned subsidiary Vergence Naturals (“Vergence”).

CB Therapeutics utilizes sustainable microorganisms and its proprietary biotechnology platform to produce therapeutic compounds found in cannabis without the land and water resource drain of growing plants.

Dr. Gary J.L. Foster and Eye Center of Northern Colorado is participating in the AcuFocus clinical study for the IC-8 intraocular lens (IOL) designed for patients with cataracts.

Palladio Biosciences, Inc. (Palladio) http://palladiobio.com/, a privately held biopharmaceutical company founded to develop medicines that make a meaningful impact on the lives of patients with orphan diseases of the kidney, today announces the dosing of the first patients with lixivaptan in ELiSA, a phase 2 clinical study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Would you buy your groceries without knowing the price? How about that new pair of jeans you’ve been coveting for months? The answer is a resounding no!

Licensing agreement includes broad coverage for more than 35 issued patent claims for improving wireless power transmission for implantable circulatory assist pumps within the lower aorta.

MedCore Partners, a national healthcare real estate development and brokerage firm headquartered in Dallas, TX, just announced the groundbreaking of its latest project, “Sunnyvale Medical Plaza.”

Palo Alto Health Sciences, Inc. (PAHS) announced today that its flagship digital therapeutic, Freespira®, has been cleared by the FDA as a treatment option for patients diagnosed with post-traumatic stress disorder (PTSD).